当前位置: X-MOL首页全球导师 国内导师 › 罗有福

个人简介

罗有福,教授,博士生导师,教育部新世纪人才获得者,四川省学术技术带头人,四川省卫计委学术技术带头人。作为项目负责人承担了“十二五”国家新药创制重大专项和“十三五”国家新药创制重大专项各1项,国家自然科学基金面上项目3项,省科技厅计划项目1项,参加多项新药创制重大专项、自然科学基金项目、省科技计划项目。累计主持企业委托项目5项。参加编写2部“十一五”国家级规划教材和2部高等学校本科教材,任“十一五”规划教材《药物及精细有机品合成》副主编,参加1部“十二五”规划教材编写。已在J Antimicrob Chemther, J Med Chem, Chem Commun, Nanoscale, Antimicrob Agents Chemother, Eur J Med Chem 等国内外期刊发表SCI论文40余篇,授权专利10余项。

研究领域

主要从事药物化学、结构生物学、药理学、化学生物学和药物设计等交叉学科方面研究工作 具体方向包括 1、小分子药物设计与合成:针对特定生物靶标,通过合理药物设计或经典药物设计理论,设计新型的、可专利化的全新骨架小分子化合物,采用常规、微波、点击化学等手段,快速合成目标分子,进行活性测定和构效关系研究,并对优选分子进行临床前转化研究。 2、结构生物学:结合世界范围内新近发现的药物靶标,开展分子克隆、蛋白表达纯化,结合基于片段的药物设计,开展具有生物活性小分子的发现及小分子和蛋白共结晶方面的研究工作。 3、药理学:对药物化学研究获得的候选药物(preclinical candidate, PCC)进行系统的体内外评价及作用靶点鉴定研究,涉及抗菌药物药理学、抗肿瘤药理学及神经精神药理学等方面的研究,主要涉及化学蛋白组学、结构生物学、分子生物学、细胞生物学、动物行为学等常用实验技术及分析方法。 4、合成方法学和合成工艺学研究:对新药研究过程中发现的新反应进行催化剂、反应条件等的优化;对候选药物(PCC)进行化学制药工艺学研究。

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Zhang, J.; Qiao, W.; Luo, Y., Mitochondrial quality control proteases and their modulation for cancer therapy. Med Res Rev 2022. Zhang, J.; Luo, B.; Sui, J.; Qiu, Z.; Huang, J.; Yang, T.; Luo, Y., IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro. Biochem Pharmacol 2022, 204, 115232. Huang, J.; Zhang, J.; Luo, B.; Qiao, W.; Qiu, Z.; Song, R.; Dai, Z.; Sui, J.; Xu, X.; Ruan, S.; Li, C.; Luo, Y.; Yang, T., Discovery of a Novel Series of Imipridone Compounds as Homo sapiens Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo. J Med Chem 2022, 65 (11), 7629-7655. Li, C.; Zhou, Y.; Xu, J.; Zhou, X.; Huang, Z.; Zeng, T.; Yang, X.; Tao, L.; Gou, K.; Zhong, X.; Chen, Q.; Luo, Y.; Zhao, Y., A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma. Eur J Med Chem 2022, 238, 114489. Li, C.; Zhou, Y.; Xu, J.; Zhou, X.; Liu, S.; Huang, Z.; Qiu, Z.; Zeng, T.; Gou, K.; Tao, L.; Zhong, X.; Yang, X.; Zhou, Y.; Su, N.; Chen, Q.; Zhao, Y.; Luo, Y., Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold. Eur J Med Chem 2022, 243, 114737. Li, C.; Liu, S.; Dong, B.; Li, C.; Jian, L.; He, J.; Zeng, J.; Zhou, Q.; Jia, D.; Luo, Y.; Sun, Q., Discovery and Mechanistic Study of Mycobacterium tuberculosis PafA Inhibitors. J Med Chem 2022, 65 (16), 11058-11065. Lei, Y.; An, Q.; Shen, X. F.; Sui, M.; Li, C.; Jia, D.; Luo, Y.; Sun, Q., Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1. J Med Chem 2021, 64 (10), 6596-6607. Song, R.; Qiao, W.; He, J.; Huang, J.; Luo, Y.; Yang, T., Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities. J Med Chem 2021, 64(6), 2851-2877. Chungen Li, Xiaowei Yang, Yuan Luo, Huan Liu, Xi Zhong, Xia Zhou, Ting Zeng, Lei Tao, Yue Zhou, Kun Gou, Xinyu Yang, Xiaocong Liu, Qiang Chen, Ying lan Zhao, Youfu Luo. Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment. J Med Chem. 2021 Dec 23;64(24):18175-18192. Jing Sui, Wenliang Qiao, Xinrong Xiang, Youfu Luo. Epigenetic changes in Mycobacterium tuberculosis and its host provide potential targets or biomarkers for drug discovery and clinical diagnosis. Pharmacol Res. 2022 Mar 29;179:106195. doi: 10.1016/j.phrs.2022.106195. Xinrong Xiang, Rui Bao, Yu Wu, Youfu Luo. Targeting mitochondrial proteases for therapy of acute myeloid leukaemia. Br J Pharmacol. 2022 Mar 30. doi: 10.1111/bph.15844. Song Liu, Wenliang Qiao, Qingxiang Sun, Youfu Luo. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor. J Med Chem 2021. PMID: 34669417 DOI: 10.1021/acs.jmedchem.1c01145. Luo B, Ma Y, Zhou Y, Zhang N, Luo Y. Human ClpP protease, a promising therapy target for diseases of mitochondrial dysfunction. Drug Discovery Today 2021 S1359-6446(21)00034-9. PMID: 33460621 DOI:10.1016/j.drudis.2021.01.007 Zhang L, He J, Bai L, Ruan S, Yang T, Luo Y. Ribosome-targeting antibacterial agents: Advances, challenges, and opportunities. Med Res Rev 2021. PMID:33501747 DOI: 10.1002/med.21780 An Q, Li C, Chen Y, Deng Y, Yang T, Luo Y. Repurposed drug candidates for antituberculosistherapy. Eur J Med Chem 2020, 192, 112175. PMID: 32126450 DOI:10.1016/j.ejmech.2020.112175 Ju Y, He L, Zhou Y, Yang T, Sun K, Song R, Yang Y, Li C, Sang Z, Bao R, Luo Y. Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers in Vitro and in Vivo. J Med Chem 2020, 63 (6), 3104-3119. PMID: 32031798 DOI:10.1021/acs.jmedchem.9b01746. Zuo Z, Liu X, Qian X, Zeng T, Sang N, Liu H, Zhou Y, Tao L, Zhou X, Su N, Yu Y, Chen Q, Luo Y, Zhao Y. Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production. J Med Chem 2020, 63 (14), 7633-7652. PMID: 32496056 DOI: 10.1021/acs.jmedchem.0c00512. Ke Sun, Yuan Ju, Chuan Chen, Peng Zhang, Erica Sawyer, Youfu Luo, Jia Geng. Single‐Molecule Interaction of Peptides with a Biological Nanopore for Identification of of Protease Activity. Small Methods.2020, doi: 10.1002/smtd.201900892 Zitai Sang, Yongping Lu, Yuanzheng Zhou,Yuan Ju, Qi An, Silan Shen, Jianyou Shi, Jun He, Tao Yang, Youfu Luo. Efficient discovery of novel antimicrobials through integration of synthesis and testing in crude ribosome extract. Chemical Communication 55, 5886–5889 (2019). PMID: 31041938 DOI: 10.1039/c9cc00144a Pingxian Liu, Yang Yang, Yunxiang Tang,Tao Yang, Zitai Sang, Zhiyong Liu, Tianyu Zhang, Youfu Luo. Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents. European Journal of Medicinal Chemistry 163,169–182 (2019). PMID: 30508666 DOI:10.1016/j.ejmech.2018.11.054 Chungen Li, Caili Chen, Qi An, Tao Yang,Zitai Sang, Yang Yang, Yuan Ju, Aiping Tong, Youfu Luo. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3). European Journal of Medicinal Chemistry 162, 543–554 (2019). PMID: 30472602 DOI: 10.1016/j.ejmech.2018.10.067 Chenzi Zhang, Xinyi Kuang, Yuanzheng Zhou, Xian Peng, Qiang Guo, Tao Yang, Xuedong Zhou, Youfu Luo, Xin Xu. A novel small molecule, ZY354, inhibits dental caries-associated oral biofilms. Antimicrobial Agents and Chemotherapy 63, (2019). PMID: 30858201 DOI:10.1128/AAC.02414-18

推荐链接
down
wechat
bug